Literature DB >> 8993292

Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response.

E M Boyle1, T H Pohlman, M C Johnson, E D Verrier.   

Abstract

Many of the components currently used to perform cardiovascular operations lead to systemic insults that result from cardiopulmonary bypass circuit-induced contact activation, circulatory shock, and resuscitation, and a syndrome similar to endotoxemia. Experimental observations have demonstrated that these events have profound effects on activating endothelial cells to recruit neutrophils from the circulation. Once adherent to the endothelium, neutrophils release cytotoxic proteases and oxygen-derived free radicals, which are responsible for much of the end-organ damage seen after cardiovascular operations. Recently the cellular and molecular mechanisms of endothelial cell activation have become increasingly understood. It is conceivable that once the molecular mechanisms of endothelial cell activation are better defined, therapies will be developed allowing the selective or collective inhibition of vascular endothelial activation during the perioperative period.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8993292     DOI: 10.1016/s0003-4975(96)01061-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  41 in total

1.  Angiopoietin-2 is a potential mediator of endothelial barrier dysfunction following cardiopulmonary bypass.

Authors:  Christian Clajus; Alexander Lukasz; Sascha David; Barbara Hertel; Ralf Lichtinghagen; Samir M Parikh; André Simon; Issam Ismail; Hermann Haller; Philipp Kümpers
Journal:  Cytokine       Date:  2012-07-06       Impact factor: 3.861

Review 2.  Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base.

Authors:  R Clive Landis; Jeremiah R Brown; David Fitzgerald; Donald S Likosky; Linda Shore-Lesserson; Robert A Baker; John W Hammon
Journal:  J Extra Corpor Technol       Date:  2014-09

3.  Perioperative methylprednisolone and outcome in neonates undergoing heart surgery.

Authors:  Sara K Pasquali; Jennifer S Li; Xia He; Marshall L Jacobs; Sean M O'Brien; Matthew Hall; Robert D B Jaquiss; Karl F Welke; Eric D Peterson; Samir S Shah; J William Gaynor; Jeffrey P Jacobs
Journal:  Pediatrics       Date:  2012-01-23       Impact factor: 7.124

4.  Risk assessment and outcomes of vasoplegia after cardiac surgery.

Authors:  Athanasios Tsiouris; Lynn Wilson; Ala S Haddadin; James J Yun; Abeel A Mangi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-13

5.  Anti-Inflammatory Effects of Taraxasterol on LPS-Stimulated Human Umbilical Vein Endothelial Cells.

Authors:  Feng Zheng; Xiaomeng Dong; Xiangzhu Meng
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

6.  Evolution of complete arterial grafting. For coronary artery disease.

Authors:  B F Buxton; J A Fuller; J Tatoulis
Journal:  Tex Heart Inst J       Date:  1998

7.  Cardiopulmonary Complications Following Cardiac Surgery.

Authors:  Renée L. Quarterman; Arthur Wallace; Mark B. Ratcliffe
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-04

8.  Peritoneal dialysis: an alternative modality of fluid removal in neonates requiring extracorporeal membrane oxygenation after cardiac surgery.

Authors:  William C Sasser; Stephen M Robert; David J Askenazi; L Carlisle O'Meara; Santiago Borasino; Jeffrey A Alten
Journal:  J Extra Corpor Technol       Date:  2014-06

9.  Perioperative indocyanine green clearance is predictive for prolonged intensive care unit stay after coronary artery bypass grafting--an observational study.

Authors:  Michael Sander; Claudia D Spies; Katharina Berger; Torsten Schröder; Herko Grubitzsch; Klaus D Wernecke; Christian von Heymann
Journal:  Crit Care       Date:  2009-09-14       Impact factor: 9.097

10.  Aprotinin attenuates the elevation of pulmonary vascular resistance after cardiopulmonary bypass.

Authors:  Tae-Jin Yun; Joon-Ryang Rho
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.